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Abstract
Background: Early-life respiratory viral infections, notably with respiratory syncytial virus (RSV), increase the risk of
subsequent development of childhood asthma. The purpose of this study was to assess whether early-life infection
with a species-specific model of RSV and subsequent allergen exposure predisposed to the development of
features of asthma.
Methods: We employed a unique combination of animal models in which BALB/c mice were neonatally infected
with pneumonia virus of mice (PVM, which replicates severe RSV disease in human infants) and following recovery,
were intranasally sensitised with ovalbumin. Animals received low-level challenge with aerosolised antigen for 4
weeks to elicit changes of chronic asthma, followed by a single moderate-level challenge to induce an
exacerbation of inflammation. We then assessed airway inflammation, epithelial changes characteristic of
remodelling, airway hyperresponsiveness (AHR) and host immunological responses.
Results: Allergic airway inflammation, including recruitment of eosinophils, was prominent only in animals that had
recovered from neonatal infection with PVM and then been sensitised and chronically challenged with antigen.
Furthermore, only these mice exhibited an augmented Th2-biased immune response, including elevated serum
levels of anti-ovalbumin IgE and IgG1 as well as increased relative expression of Th2-associated cytokines IL-4, IL-5
and IL-13. By comparison, development of AHR and mucous cell change were associated with recovery from PVM
infection, regardless of subsequent allergen challenge. Increased expression of IL-25, which could contribute to
induction of a Th2 response, was demonstrable in the lung following PVM infection. Signalling via the IL-4 receptor
a chain was crucial to the development of allergic inflammation, mucous cell change and AHR, because all of
these were absent in receptor-deficient mice. In contrast, changes of remodelling were evident in mice that
received chronic allergen challenge, regardless of neonatal PVM infection, and were not dependent on signalling
via the IL-4 receptor.
Conclusion: In this mouse model, interaction between early-life viral infection and allergen sensitisation/challenge
is essential for development of the characteristic features of childhood asthma, including allergic inflammation and
a Th2-biased immune response.
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Asthma is one of the most common chronic diseases in
children in industrialised societies [1]. The association
between childhood infections and asthma is complex,
because at least in some settings, repeated exposure to
infectious agents may reduce the likelihood of develop-
ing allergic diseases [2]. However, epidemiological stu-
dies strongly suggest that lower respiratory viral
infections associated with wheezing, especially in early
childhood, play an important role in the subsequent
development of asthma in children who are repeatedly
exposed to inhaled allergens [3-8].
Respiratory syncytial virus (RSV) infection, particularly
severe disease with bronchiolitis in children under 1
year, has a strong linkage to allergic asthma [9,10]. The
underlying mechanisms remain unknown, in large part
because investigation in animal models is confounded
by the species specificity of pneumoviruses. There is lit-
tle if any replication of human RSV in mice, so that
murine models using this virus require a very large
inoculum (>10
4 pfu) [11,12]. By comparison, infection
with pneumonia virus of mice (PVM), which belongs to
t h es a m ef a m i l y( Paramyxoviridae) and genus (Pneumo-
virus) as RSV [13], provides a realistic model of RSV
disease. Because PVM is a natural rodent pathogen, far
fewer virions are required to induce infection. As little
as 2 pfu elicits a respiratory tract infection, ~30 pfu pro-
vokes a productive infection with severe bronchiolitis,
and 300 pfu results in rapid death [11]. In its full-blown
form, PVM infection induces severe pulmonary inflam-
mation with recruitment of neutrophils and marked
oedema, thus resembling acute respiratory distress syn-
drome [14]. This is paralleled by marked respiratory
dysfunction as assessed by whole body plethysmography,
which is accompanied by local production of pro-
inflammatory mediators including MIP-1a,M I P - 2 ,
MCP-1 and IFN-g [15]. MIP-1a and IFN-g are crucial to
granulocyte recruitment [14,16].
Investigating the link between an early-life viral infec-
tion and childhood asthma also requires an appropriate
model of allergen sensitisation and long-term challenge.
We have previously established murine models of mild
chronic asthma and an allergen-induced acute exacerba-
tion [17,18]. Hallmarks of these models include control
of the mass concentration of aerosolised antigen to
which animals are exposed, facilitating induction of
lesions corresponding in their spatial distribution to
those observed in the human disease. Low-level chal-
lenge over periods of 4 or more weeks induces chronic
inflammation and remodelling which in contrast to
other models is limited to conducting airways, with
minimal parenchymal inflammation. Subsequent delivery
of a single moderate-level challenge elicits features of an
acute exacerbation, characterised by distal airway
inflammation with eosinophil recruitment [18].
In this study, we have employed a unique combination
of these models to provide direct experimental evidence
for an interaction between early-life infection with a
pneumovirus and allergen sensitisation/challenge in the
development of an asthmatic phenotype. We found that
key features of the asthmatic response, notably eosino-
phil recruitment and an associated Th2 cytokine
response, were detected only in the groups of mice that
had recovered from neonatal infection with PVM and
were then subjected to chronic antigen challenge. Induc-
tion of these features was abrogated in mice deficient in
their ability to express the IL-4 receptor a chain, indi-
cating a crucial role for signalling via this receptor.
Furthermore, we found that IL-25 was upregulated fol-
lowing viral infection, suggesting a possible mechanism
by which a Th2-biased response might be triggered.
This novel experimental system provides opportunities
for investigation of pathogenetic mechanisms of child-
hood asthma, as well as for potential interventions.
Methods
Animals
Pregnant specific pathogen-free wild-type BALB/c mice
were obtained from Animal Services, University of New-
castle. To assess the contribution of signalling via the
IL-4 receptor, which is utilised by both IL-4 and IL-13,
responses were compared in mice on the same genetic
background but deficient in their ability to express the
IL-4 receptor a chain (IL-4Ra
-/-) [19]. During infection
and allergen sensitisation, neonatal and weanling mice
were maintained in individually ventilated cages in the
animal housing facility, David Maddison Building, Uni-
versity of Newcastle. At 5-6 weeks of age, mice were
transported to the University of New South Wales
where they were maintained in a laminar flow holding
unit (Gelman Sciences, Australia) and housed in auto-
claved cages, in an air-conditioned room on a 12 hour
light/dark cycle. Additional control animals, specific
pathogen-free female BALB/c mice aged 8 weeks, were
purchased from the Animal Resources Centre, Perth
and held at the University of New South Wales through-
out the duration of the study. Irradiated food and acidi-
fied water were provided ad libitum throughout. All
experimental procedures complied with the require-
ments of the Animal Care and Ethics Committee of the
University of New South Wales (ref no. 09/116B) and
the University of Newcastle (ref no. 1026).
PVM infection, allergen sensitisation and inhalational
challenge
The various experimental and control groups used in
preliminary studies to establish the model are shown in
Siegle et al. Respiratory Research 2010, 11:14
http://respiratory-research.com/content/11/1/14
Page 2 of 15Figure 1. These permitted assessment of the effects of
recovery from neonatal viral infection, sensitisation at
different time points, and chronic inhalational challenge,
either alone or in combination. For each experiment,
groups comprised 8 mice, and all findings were con-
firmed in at least 2 separate experiments. Infection of
neonatal mice with PVM used mouse passaged PVM
J3666 strain (~1 × 10
5 pfu/ml). On both days 1 and 2 of
life, mice were intranasally inoculated with 2 pfu in 5 μl
phosphate buffered saline (PBS) on the external nares.
Control animals were sham-infected with PBS alone.
Intranasal sensitisation to chicken egg ovalbumin (Grade
V, ≥ 98% pure, Sigma Australia, Australia) was per-
formed either at days 1 and 2 of life or at days 28 and
29, with 5 μgO V A / 5μlP B So r1 0 0μg/40 μlr e s p e c -
tively (Figure 1).
Inhalational challenge to aerosolised ovalbumin was
performed as previously described [17,18]. Briefly, com-
mencing at 7 weeks of age, BALB/c mice or IL-4Ra
-/-
mice received low-level aerosol challenge with ovalbu-
min (mass concentration of ≈ 3 mg/m
3 of ovalbumin for
30 min/day, 3 days/week for 4 weeks). This was fol-
lowed by a single moderate-level challenge (≈ 30 mg/m
3
for 30 minutes) to induce the changes of an acute
exacerbation (Figure 1). During inhalation exposures,
mice were held in flow-through wire cage racks (Unifab
Corporation, Kalamazoo, Michigan, USA). Filtered air
was drawn through the inhalation chamber (0.5 m
3)a ta
flow rate of 250 L/min, and an aerosol of ovalbumin
was generated from a 2.5% solution by controlled
delivery of compressed air to a sidestream nebuliser
(Trimed, Australia). Particle concentration within the
chamber was continuously monitored using a DustTrak
8520 instrument (TSI, St Paul, MN).
Bronchoalveolar lavage and histopathology
Four hours after the final aerosol challenge, mice were
killed by exsanguination following an overdose of
sodium pentobarbital. Bronchoalveolar lavage (BAL)
fluid was collected and total cell counts were performed.
Differential cell counts were assessed on at least 300
cells in a Leishman-stained smear [18].
Following perfusion and BAL fluid collection, the left
lung was inflated and fixed in 10% buffered formalin
[17]. The longitudinally orientated trachea and a hori-
zontal slice from the mid zone were embedded in paraf-
fin and used to assess inflammation and changes of
remodelling. The right lung was collected, diced into
small fragments and stored in Tri-reagent for RNA
extraction. An additional 8 animals per group had 0.8 -
1.0 ml OCT compound (ProSciTech, Australia) instilled
into the left lung, with a horizontal slice from the mid
zone collected and frozen in liquid nitrogen.
Morphometry
Immunoperoxidase staining for CD3
+ T-lymphocytes in
frozen lung tissue was performed using rabbit anti-
human antibodies against CD3 (Sigma-Aldrich, Austra-
lia). Eosinophils in lung tissue were identified using a
cyanide-resistant peroxidase staining technique [20,21].
Briefly, acetone fixed, frozen lung sections were incu-
bated in a 5 mM potassium cyanide solution for 10
Figure 1 Experimental design. Diagrammatic representation of protocol for infection, sensitisation and inhalational challenge.
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trophils and macrophages. Following a thorough wash,
slides were incubated in diaminobenzidine solution for 5
minutes and counterstained with methyl green. Eosino-
phils were quantified at 40× magnification using Spot
imaging software. Results were expressed as number of
cells per mm
2 of parenchymal tissue.
Inflammation in the airway wall was quantified in hae-
matoxylin and eosin-stained sections of trachea. Intrae-
pithelial eosinophils and nuclear profiles in the lamina
propria were counted and the length of the epithelial
basement membrane was measured at 40× magnifica-
tion. Results were expressed as number of cells per 100
μm basement membrane, as previously described [17].
Lymphoid aggregates adjacent to small airways were
enumerated in haematoxylin and eosin-stained sections
of lung tissue.
Subepithelial collagenisation and epithelial hypertro-
phy were assessed in reticulin stained trachea as pre-
viously described [17]. Goblet cell changes were assessed
in periodic acid schiff (PAS) stained lung tissue. The lar-
gest visible airway, usually the left main bronchus, was
assessed in each section. Positively stained cells were
semi-quantitatively graded on a scale from 0-4, where a
grade of 0 = <1% positive cells, 1 = 1-3%, 2 = 4-10%, 3
= 11-30%, and 4 = ≥ 31%.
Airway hyperresponsiveness
Airway responsiveness to inhaled b-methacholine was
measured by assessing transpulmonary resistance (RL)4
hours after the final aerosol challenge [18,22]. Mice
were challenged with saline to establish baseline
responses, then with increasing concentrations of b-
methacholine (6.25, 12.5, 25 and 50 mg/ml). Aerosols
were generated with an ultrasonic nebuliser (Buxco,
Aeroneb Laboratory Nebulizer) and delivered to the
inspiratory line. Each aerosol was delivered for a period
of 5 minutes and a computer program (BioSystemXA,
Buxco Electronics, Inc.) was used to calculate pulmonary
resistance from the continuously recorded pressure and
flow data. Peak pulmonary resistance values were taken
as the maximum response to the concentration of
methacholine being tested, and are expressed as the per-
cent change over the saline control. Dose-response
curves were plotted for each animal and the area under
the curve was calculated.
Cell isolation
CD4
+ T-lymphocytes were isolated from pooled pairs of
lungs four hours after the final challenge. Briefly, lung
tissue was diced into fine fragments (<0.3 mm
3) and dis-
persed in a mixture of Type IV collagenase (Worthing-
ton Biochemical, Lakewood, NJ) and DNase (Roche
Diagnostics, Australia). Following incubation on a roller
mixer for 40 minutes at 37°C, samples were vortexed
and passed through a 70 μm cell strainer. Cells were re-
suspended in red cell lysis buffer and washed with PBS.
This yielded a mixed population of cells, the majority of
which were lymphocytes and macrophages. Cell viability
was >90% in all samples. CD4
+ T cells were then iso-
lated using a Mouse CD4 FlowComp™ magnetic bead
isolation kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. This method yields ~98.0%
pure CD4
+ T cell populations. A total of 5 × 10
5 cells
were suspended and lysed in Tri-reagent (Sigma Austra-
lia, Australia) for RNA extraction, while the remaining
cells were kept on ice until ready to use in enzyme-
linked immunospot (ELISpot) assays. From some groups
of animals, blood was also collected by cardiac puncture
and serum was stored at -20°C for later analysis.
Enzyme immunoassays
PVM-specific IgG antibodies were measured from sham-
infected and virus-infected animals using the SMART
M12 kit (Biotech Trading Partners, El Cerrito, CA).
Briefly, appropriate controls and serum samples were
incubated at room temperature for 30 minutes. Wells
were washed 5 times after this and each subsequent
incubation. One drop of enzyme conjugate was added to
each well and incubated for 30 minutes, which was fol-
lowed by the chromogen substrate for 10 minutes. Reac-
tions were subsequently stopped with phosphoric acid,
and plates were read on a Bio-Rad microplate reader
(680XR) at 450 nm.
OVA-specific IgE in serum was measured using a
commercial kit (MD Biosciences, St Paul, MN) accord-
ing to the manufacturer’s instructions. Ovalbumin-speci-
fic IgG1 in serum was measured as previously described
[23]. Briefly, appropriate wells were coated with either
anti-IgG1 (BD Pharmingen) or ovalbumin (2 μg/well).
After blocking, wells were incubated with serial dilutions
of serum or standards (mouse IgG1), followed by detec-
tion with streptavidin HRP anti-IgG1. Plates were devel-
oped and read at 450 nm using a BioRad 680
Microplate reader. Samples were measured in duplicate
and the sensitivity of detection was 3 ng/ml.
Enzyme-linked immunospot assays
Cytokine secretion by CD4
+ T cells was assessed using
MultiScreenHTS-HA Filter Plates (Millipore, Australia)
coated with appropriate antibodies (R&D Systems, Aus-
tralia) according to the manufacturer’s instructions. Iso-
lated CD4
+ T cells were cultured in RPMI 1640
(containing 10% FBS, 1% penicillin/streptomycin, 1% L-
glutamine, 1% Non-essential amino acids, 1% sodium
pyruvate) at 2 × 10
5 cells/well in the presence of 1 mg/
ml ovalbumin for 24 hours. Appropriate detection anti-
bodies (R&D Systems, Australia) were added to wells
and the plate was incubated overnight. Following wash-
ing, a working solution of streptavidin-AP (1:1000)
(MabTech Australia Pty Ltd, Australia) was added to
each well and left at room temperature for 2 hours.
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was used to develop spots, which took up to 30 minutes.
Spots were detected using the AID ELISpot reader
(Autoimmun Diagnostika, Germany).
RNA isolation and polymerase chain reaction
Extraction of mRNA from whole lung and CD4
+ Tc e l l s
was performed using Tri-reagent (Sigma Australia, Aus-
tralia) according to the manufacturer’s instructions.
RNA concentrations were measured using a NanoDrop
ND-100 spectrophotometer (NanoDrop Technologies,
Wilmington, DE). Viral load was assessed 2, 4, 7, 14, 21
and 28 days post infection in whole lung. Samples were
reverse transcribed with the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, Australia) and
M-MLV-RT (Invitrogen). Expression of PVM was
assessed by real time PCR, with SYBR green to detect
amplified products. Primer sequences were as follows:
PVM forward 5’-GCCTGCATCAACACAGTGTGT-3’
and reverse 5’-GCCTGATGTGGCAGTGCTT-3’
[24,25]. IL-25 levels were similarly assessed in whole
lung at 14 and 28 days, while Gob5 levels were assessed
in whole lung at day 78.
For isolated CD4
+ T cells, mRNA was treated with
Turbo DNase (Ambion Inc., Austin, TX, USA) and sam-
ples reverse transcribed using SuperScript® III First
Strand Synthesis System (Invitrogen, Australia) accord-
ing to the manufacturer’s instructions. Expression of
cytokines and transcription factors was assessed via
quantitative RT-PCR, with SYBR green used to detect
amplified products. Primers were either kindly provided
by Dr. Ken Hsu (University of New South Wales), taken
from an external reference [26] or designed using Pri-
mer Express software (Applied Biosystems, Australia).
Real-time reactions were performed using an ABI Prism
7700 Sequence Detection System (Applied Biosystems,
Australia), and gene expression was normalised to
hypoxanthine phosphoribosyltransferase (HPRT).
Statistical Analysis
Results are presented as arithmetic mean (S.E.M.) or as
medians (interquartile range). For comparison between
multiple groups, differences compared to the relevant
control group were assessed using one-way ANOVA or
the corresponding non-parametric Kruskal-Wallis test,
followed by either a Dunnett’s test or Bonferroni-cor-
rected t tests as appropriate. The software package
GraphPad Prism (GraphPad Software, San Diego, Cali-
fornia, USA) was used for all data analysis and prepara-
tion of graphs.
Results
PVM infection and recovery
I n t r a n a s a li n o c u l a t i o no fP V Ma td a y s1a n d2o fl i f e
effectively established viral infection, with viral load
peaking at day 7 (Figure 2A). By day 14 viral load had
decreased substantially, with clearance achieved at 4
weeks after infection. The mice did not develop any visi-
ble clinical manifestations of infection and there was no
excess mortality. However, mean weight was signifi-
cantly decreased at 14 and 21 days after infection (Fig-
ure 2B). Enumeration of BAL cells in 14 day old mice
revealed an increased total number of cells, as well as
increases in the numbers of neutrophils, eosinophils and
lymphocytes (not shown). Viral infection led to serocon-
version, assessed at 11 weeks following infection (not
shown).
Development of lesions in response to infection and/or
allergen exposure
Inflammatory response
A modest increase in the number of CD3
+ T cells in
lung tissue, identified by immunostaining, was noted fol-
lowing either an early-life viral infection alone or oval-
bumin sensitisation and challenge, although these
increases were not statistically significant (Table 1). In
contrast, the combination of recovery from PVM infec-
tion and OVA challenge, with or without intranasal sen-
sitisation at days 28 and 29, led to a significant increase
in the number of intrapulmonary T cells compared to
naïve animals (P < 0.05). By comparison, OVA sensitisa-
tion at days 1 and 2, with or without viral infection, was
not associated with a significant increase in CD3
+ T
cells in response to chronic challenge (Table 1).
Recovery from PVM infection was associated with the
presence of small lymphoid aggregates in the lung tis-
sue, usually adjacent to small airways, with the typical
morphology of inducible bronchus-associated lymphoid
tissue (iBALT) including a peripheral zone of CD3-posi-
tive cells (Figure 3A) [27]. Numbers of iBALT aggre-
gates were somewhat reduced in mice that were
sensitised and challenged with OVA, except in the case
of IL-4Ra
-/- mice (Table 1).
Acute allergic inflammation, with accumulation of
eosinophils within airway epithelium (Figure 3B) and in
lung tissue, was demonstrable in animals that recovered
from an early-life PVM infection and then received
OVA sensitisation at days 28 and 29 followed by chronic
challenge. Numbers of intrapulmonary eosinophils were
significantly increased only in the virus/OVA group (P <
0.01) (Table 1).
I nt h el a m i n ap r o p r i ao ft h ec o n d u c t i n ga i r w a y s ,s i g -
nificantly increased numbers of chronic inflammatory
cells were evident in chronically challenged mice follow-
ing either recovery from PVM infection, sensitisation
with OVA at days 28 and 29, or both (P < 0.05). In ani-
mals which were sensitised at days 1 and 2 of life, there
was no such increase in the number of inflammatory
cells (Table 1).
The role of signalling via the IL-4 receptor was
demonstrated by the observation that in IL-4Ra
-/- mice
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then received OVA sensitisation followed by chronic
challenge, development of both acute and chronic com-
ponents of the allergic inflammatory response was com-
pletely suppressed (Table 1).
Airway wall remodelling
Subepithelial collagenisation (at least P < 0.01) was
apparent in all groups of mice that were chronically
challenged with OVA, except the group of sham
infected and sensitised animals (Table 1 and Figure 3C,
D). There were no significant changes in mice that
recovered from neonatal PVM infection but were not
sensitised or challenged. Significant epithelial hypertro-
phy (at least P < 0.05) was evident in mice sensitised
with OVA at days 28 and 29 of life and chronically
challenged (Table 1 and Figure 3C, D), but not in those
sensitised at days 1 and 2 of life. Again, no significant
changes were observed in mice that recovered from neo-
natal PVM infection but were not sensitised or chal-
lenged. Changes of remodelling were not related to
signalling via the IL-4 receptor, as responses similar to
those seen in the virus/OVA group were also observed
in the infected, sensitised and challenged IL-4Ra
-/- mice
(Table 1).
Mucin-secreting PAS positive cells were infrequently
observed in the epithelium of naïve mice (Figure 3E).
Significant metaplasia/hyperplasia of goblet cells (at least
P < 0.05) was associated with PVM infection at birth
(Table 1 and Figure 3F), while a lesser increase (not sta-
tistically significant) was also observed in OVA-
Figure 2 PVM infection. (A) PVM load assessed by PCR of lung tissue at 2-28 days post-infection. Levels of virus in samples from infected
animals at days 2, 4 and 28 were at or below the limits of detection, as were levels in all samples from sham-infected control animals. (B) Mean
weights of PVM-infected and naïve mice during the first 3 weeks of life. Significant differences shown as * = P < 0.05, ** = P < 0.01.
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early-life infection with PVM. Corresponding with
mucous cell changes, expression of mRNA for Gob5 was
significantly increased (approximately 50 fold, P < 0.05
for the virus/OVA group) in the lung tissue of animals
that had recovered from viral infection (Figure 4).
Mucous cell metaplasia/hyperplasia was much less
marked in animals sensitised at days 1 and 2 of life and
was completely absent in the infected, sensitised and
challenged IL-4Ra
-/- mice (Table 1).
Airway responsiveness
At 4 hours after the final challenge, all groups of wild
type mice that had recovered from PVM infection
exhibited a significant increase in RL, compared to naïve
control animals (Figure 5). This was dependent on sig-
nalling via the IL-4 receptor, as AHR was absent in
infected, sensitised and challenged IL-4Ra
-/- mice. Nota-
bly, OVA sensitisation and challenge without early-life
viral infection did not elicit AHR.
Interaction between infection and allergen exposure
To investigate the interaction between infection and
chronic allergen challenge, airway and pulmonary
inflammation were assessed in parallel with cytokine
and transcription factor expression by pulmonary CD4
+
T cells. These studies excluded animals sensitised at
days 1 and 2, which exhibited down-regulated responses.
Because the responses of sham-infected and sham-sensi-
tised animals were indistinguishable from those of naïve
animals, the latter were used as controls for these
experiments.
Inflammatory response
Cells from BAL were collected for total and differential
counts, while pulmonary CD4
+ cells recovered from dis-
aggregated tissue and intraepithelial eosinophils in
sections of trachea were enumerated in parallel. As
shown in Table 2, a markedly increased yield of BAL
cells was observed only in the virus/OVA chronically
challenged group and this was significantly greater than
in either the virus control group or the sham/OVA
chronically challenged group (P < 0.001 for both com-
parisons). Paralleling these observations was a significant
increase in the recovery of CD4
+ cells from the virus/
OVA group (P < 0.001 compared to the virus control
group, P < 0.01 compared to the sham/OVA group, Fig-
ure 6A). Similarly, as shown in Figure 6B, numbers of
intraepithelial eosinophils were highest in the virus/
OVA group (P < 0.01 compared to the virus control
group) although a moderate increase was also noted in
the sham/OVA group.
Anti-OVA IgE and IgG1 response
Serum levels of ovalbumin-specific IgE were significantly
increased only in the virus/OVA chronically challenged
group (P < 0.05 compared to the virus control group)
(Figure 6C). Similarly, levels of ovalbumin-specific IgG1,
which is induced in parallel with IgE in mice [28], were
most strikingly increased in the virus/OVA chronically
challenged group (P < 0.01 compared to the virus con-
trol group, P < 0.05 compared to the sham/OVA group)
(Figure 6C).
Pulmonary CD4
+ T cell cytokine profile
Assessment of the expression of Th1 and Th2 cytokines
and their corresponding transcription factors revealed
that only in mice which had recovered from early-life
PVM infection and then been sensitised and chronically
challenged with OVA was there a Th2-biased immuno-
logical profile. In CD4
+ T cells from these animals,
there was significantly elevated relative expression of IL-
4 (P < 0.05 compared to both the virus control group
Table 1 Inflammatory and epithelial changes in the airways and lungs
Experimental groups
Naive Virus
control
Sham/
sham
Sham/
OVA
Virus/nil Virus/
OVA
OVA/
sham
Virus
+OVA/nil
Virus/OVA IL-
4Ra
-/-
Intrapulmonary CD3
+ T cells/mm
2 2.8
(0.8)
7.2 (0.9) 3.3 (0.6)
# 8.0 (1.3) 10.4 (3.2)
*
10.2 (2.2)
*
4.4 (0.9) 6.6 (0.8) 4.7 (1.2)
Intrapulmonary eosinophils/mm
2 2.7
(0.6)
3.7 (0.9)
# 1.5 (0.4)
###
3.7 (1.1)
# 3.0 (0.8)
# 6.5 (0.6)
***
1.1 (0.5)
###
5.7 (0.9) 0.9 (0.3)
###
Lymphoid aggregates per section
§ 0.0
(0.75)
2.0 (3.25) * 0.0 (0.25) 0.0 (1.25) 1.0 (4.0) 1.0 (2.0) 0.5 (1.0) 1.0 (1.25) 2.5 (4.75) **
Lamina propria cells/100 μm basement
membrane
19.2
(1.0)
22.3 (1.1) 19.6 (1.7)
# 24.0 (1.2)
*
24.8 (1.5)
*
25.1 (1.2)
*
20.0 (1.5) 22.0 (1.6) 21.7 (1.0)
Thickness of subepithelial collagen
zone (μm)
3.2
(0.2)
4.0 (0.2) 2.7 (0.2)
###
4.7 (0.2)
***
4.3 (0.2)
**
4.8 (0.1)
***
4.2 (0.2)
*
4.2 (0.2) * 4.4 (0.4) **
Thickness of epithelial cell layer (μm) 12.5
(0.5)
12.6 (0.8)
# 12.1 (0.7)
##
16.9 (0.5)
***
15.1 (0.7) 16.1 (1.3)
*
14.6 (0.7) 13.7 (0.9) 16.2 (0.6) *
Grade of mucous cell metaplasia
§ 1.0
(1.0)
3.0 (3.0)* 0.0 (1.0)
## 2.0 (2.0) 3.0 (2.0)
**
3.0 (1.0)
**
2.0 (2.0) 1.0 (2.0) 0.0 (0.0)
###
Data are presented as mean (S.E.M), except
§ which are median (interquartile range). Significant differences compared to naïve animals shown as * = P < 0.05, **
= P < 0.01, *** = P < 0.001; compared to virus-infected, OVA-challenged animals (Virus/OVA) shown as
# =P<0 . 0 5 ,
## =P<0 . 0 1 ,
### = P < 0.001.
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Figure 3 Histopathological changes. (A) A lymphoid aggregate adjacent to a bronchiole, in lung tissue from an animal from the virus-infected
control group at 11 weeks of age. (B) An eosinophil within the tracheal epithelium (arrow) from a mouse from the virus/OVA group. (C)
Reticulin-stained trachea from a naïve animal demonstrating normal thickness of subepithelial collagenous zone (black arrow) and epithelial layer
(red arrow). (D) Trachea from a mouse infected with PVM at birth, then sensitised to OVA and challenged (virus/OVA group) demonstrating
significant thickening of both the subepithelial collagenous zone (black arrows) and the epithelium (red arrow). (E) Left main bronchus from a
naïve animal stained with PAS, showing that no mucin-producing cells are present (grade 0). (F) Left main bronchus from a mouse from the
virus/OVA group, demonstrating numerous PAS-positive goblet cells in the epithelium (arrows) (grade 4). Scale bar = 150 μmi nA ,2 5μmi nB
and 50 μm in C-F.
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Page 8 of 15and the sham/OVA group), IL-5 (P < 0.05 compared to
the virus control group) and IL-13 (P < 0.001 compared
to the virus control group, P < 0.01 compared to the
sham/OVA group) (Figure 6D-F). In contrast, recovery
from PVM infection or OVA sensitisation and challenge
were not by themselves associated with significantly
increased Th2 cytokine expression, compared to naïve
animals. As expected, no increase in expression of Th2
cytokines was demonstrable in IL-4Ra
-/- mice (not
shown).
Expression levels of GATA-3, the Th2 associated tran-
scription factor, mimicked the pattern of the major Th2
cytokines, although the magnitude of these changes was
not statistically significant. Levels of IFN-g expression
were not increased in any of the experimental groups,
nor was there any increase in the expression of T-bet,
the Th1 associated transcription factor (data not shown).
Because our models involve challenge with the rela-
tively low mass concentrations of aerosolised OVA,
assessment of levels of inflammatory cytokines in BAL
fluid is not feasible. Therefore, we attempted to assess
secretion of Th1 and Th2 cytokine proteins in superna-
t a n t so fs h o r t - t e r mc u l t u r e so fC D 4
+ Tc e l l sr e s t i m u -
lated with OVA ex vivo, but these concentrations also
fell below the limits of detection in a multiplex assay.
Accordingly, we assessed secretion by isolated CD4
+ T
cells using ELISpot assays. Only cells from animals that
had recovered from PVM infection and then been sensi-
tised and challenged with OVA exhibited significantly
increased secretion of IL-4 and IL-13 (Table 3). These
animals also exhibited enhanced secretion of IL-5,
although this increase was not statistically significant. In
contrast, there was no evidence of increased secretion of
IFN-g in any of the experimental groups.
Expression of IL-25 in lung tissue
To assess the possible role of epithelial injury by early-
life PVM infection in the induction of a Th2-biased
immunological response, we assessed relative expression
of mRNA for IL-25 in lung tissue at days 14 and 28 of
life. As shown in Table 4, IL-25 expression at day 14
was significantly up-regulated (P < 0.001 compared to
sham-infected animals, t-test). Levels were also
i n c r e a s e da td a y2 8b u tb e c a u s eo ft h es c a t t e ro fi n d i v i -
dual sample values, this increase was not statistically
significant.
Discussion
Epidemiological studies have clearly demonstrated an
association between early-life viral infections, allergen
exposure and subsequent development of childhood
asthma. While these factors appear to be synergistic [4],
the relationship remains poorly understood [29] and is
difficult to investigate in the absence of an appropriate
experimental model. In this study we have, for the first
time, demonstrated this interaction in a clinically rele-
vant model of childhood asthma. Our model has parti-
cular advantages because it employs PVM, a species-
specific pneumovirus that replicates in mouse lung tis-
sue, induces marked inflammation and thus models the
full spectrum of pathological changes of human RSV
disease in early life [30,31]. This is in contrast to murine
experimental models based on human RSV, which uti-
lise extraordinarily high inocula but still achieve little or
no virus replication and thus elicit little or no antiviral
inflammatory response [12,32]. Because RSV infection
within the earliest months of life is most clearly related
to subsequent development of asthma, and because pre-
vious studies have established that the pattern of host
response to pneumovirus infection is age-dependent
[33,34], we specifically examined responses only in mice
infected with PVM in the first two days of life.
To further emulate the earliest phases of induction of
asthma in childhood, our model involved sensitisation
via the respiratory tract. We then employed chronic
low-level challenge with aerosolised OVA followed by a
single moderate-level challenge, using mass concentra-
tions of aerosolised antigen at least 10-100 fold lower
than in commonly used short-term experimental sys-
tems [18]. The magnitude of the inflammatory response
observed was therefore relatively modest, but as in our
previously described models based on systemic sensitisa-
tion [17,18], we elicited key features of chronic asthma
that resembled the human disease and were limited to
conducting airways (eosinophil recruitment into the
epithelial layer, chronic inflammation in the airway wall,
and changes of remodelling such as subepithelial
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Figure 4 Expression of Gob5. mRNA expression for Gob5 assessed
by PCR of lung tissue. Significant difference compared to naïve
animals shown as * = P < 0.05.
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Page 9 of 15fibrosis, epithelial hypertrophy and goblet cell metapla-
sia). Following the final moderate-level challenge, we
also elicited features of an exacerbation of asthma (distal
airway inflammation with increased recruitment of
eosinophils).
Our key finding was that it was only in the setting of
early-life viral infection followed by sensitisation via the
respiratory tract that several crucial elements of the
asthmatic phenotype developed, with allergen challenge
then able to elicit inflammation typical of both chronic
stable asthma and an acute exacerbation. Recovery from
viral infection, or allergen sensitisation and challenge,
were separately each able to induce some elements of
airway inflammation, remodelling or hyperresponsive-
ness to a cholinergic stimulus. The pattern of responses
is summarised in Table 5 and provides insight into the
relative contributions of prior viral infection and aller-
gen exposure to the development of the lesions of child-
hood asthma.
Specifically, the co-operative interaction between
early-life infection and allergen challenge for induction
of asthmatic inflammation was apparent in terms of
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Figure 5 Development of AHR. (A) Airway responsiveness to increasing concentrations of b-methacholine, assessed by transpulmonary
resistance (RL). (B) Transpulmonary resistance assessed as area under the curve. Significant differences compared to naïve animals shown as * =
P < 0.05, ** = P < 0.01, *** = P < 0.001; compared to virus-infected, OVA-challenged animals (Virus/OVA) shown as ## = P < 0.01.
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Page 10 of 15recruitment of eosinophils into the airways, as well as
corresponding increases in the number of BAL cells and
of CD4
+ T cells recovered from lung tissue. Inflamma-
tion was also closely allied with development of a Th2-
biased immunological response. Mucous cell change and
AHR were associated with recovery from early-life viral
infection alone, but like asthmatic inflammation, were
dependent on signalling via the IL-4 receptor. In con-
trast, we found that changes of subepithelial fibrosis and
epithelial hypertrophy in the conducting airways were
associated with allergen sensitisation and chronic chal-
lenge alone. Airway remodelling did not appear to be
dependent on either signalling via the IL-4 receptor or a
Th2-biased response, but could be related to production
of growth factors such as TGF-b and IGF-1 by airway
epithelial cells, which we have previously demonstrated
following chronic inhalational challenge [35].
Our data are consistent with findings in biopsy studies
of children either at risk for or with established asthma,
which suggest that subepithelial fibrosis develops during
the early induction phase. Indeed there is now consider-
able evidence that, contrary to previously held views,
changes of remodelling precede or occur in parallel with
inflammation, and are evident well before the diagnosis
of childhood asthma [36-40]. They are also consistent
with patient data indicating that AHR may be disso-
ciated from asthmatic inflammation and precede the
development of clinical asthma [36,41]. However, the
relationship between subepithelial fibrosis, airway
inflammation and AHR has not previously been assessed
in an experimental model of childhood asthma.
In the present study, AHR was primarily related to
recovery from neonatal infection with PVM, as well as
to expression of mRNA for Gob5 and to goblet cell
hyperplasia/metaplasia. Gob5 (also known as mClca3)i s
a calcium-dependent chloride channel which has key
roles in the development of mucous cell change and
AHR [42,43], so this correlation is of particular interest.
Enhanced expression of Gob5 is likely to be a response
to injury of epithelial cells, which are the primary site of
replication of pneumoviruses. As noted above, AHR was
also dependent on signalling via the IL-4 receptor, sug-
gesting a role for cytokines such as IL-4 and IL-13. Pre-
vious studies of RSV infection in weanling mice have
demonstrated induction of AHR that may persist for up
to 24 weeks [44], which is consistent with the presence
of AHR in mice which recovered from neonatal infec-
tion with PVM.
Our study also provides evidence that in this model,
the underlying mechanism of development of an asth-
matic inflammatory response is recruitment and activa-
tion of pulmonary T cells, with induction of a Th2-
biased immunological response. Only in animals that
recovered from a neonatal infection with PVM, then
were sensitised by intranasal administration of OVA and
subsequently challenged with aerosolised allergen was
there evidence of high levels of anti-OVA IgE and IgG1,
together with increased numbers of pulmonary CD4
+
cells which expressed elevated levels of mRNA for IL-4,
IL-5, IL-13 and GATA-3, as well as enhanced secretion
of IL-4, IL-5 and IL-13. In IL-4Ra
-/- mice, in which Th2
responses are abrogated because the IL-4 receptor a
chain is involved in signalling for both IL-4 and IL-13,
development of asthmatic inflammation, mucous cell
change or AHR was prevented. Evidence of the impor-
t a n c eo fi n d u c t i o no faT h 2 - b i a s e dr e s p o n s ei so fp a r t i -
cular interest, as this is clearly of clinical relevance in
childhood asthma [45] and recent studies suggest that
inhibition of IL-4Ra can reduce some of the clinical
manifestations in patients with atopic asthma [46].
Furthermore, our observations suggest a key role for
early-life viral infection in breaking tolerance to antigen,
because neonatal exposure to ovalbumin via the respira-
tory tract otherwise induces tolerance [47,48]. However,
the timing of sensitisation had a critical impact on the
development of asthmatic lesions, so that inflammation
Table 2 BAL cellular response
Groups Total Macrophages Lymphocytes Neutrophils Eosinophils
Naïve 263 (34.1) 259 (1.8) 3 (1.3) 0 (0.3) 1 (0.8)
98.3% (0.7) 1.3% (0.5) 0.1% (0.1) 0.3% (0.3)
Virus control 312 (19.8) 262 (5.6) 47 (4.7) 1 (0.3) 1 (0.3)
84.1% (1.8) *** 15.1% (1.5) *** 0.2% (0.1) 0.2% (0.1)
Sham/OVA 171 (20.5) 145 (4.8) 24 (3.4) 2 (1.7) 0 (0.2)
84.7% (2.8) *** 14.0% (2.0) *** 1.2% (1.0) 0.1% (0.1)
Virus/nil 330 (41.7) 275 (5.3) 47 (3.3) 7 (3.3) 0 (0.3)
83.3% (1.6) *** 14.3% (1.0) *** 2.2% (1.0) 0.1% (0.1)
Virus/OVA 555 (60.0) *** 429 (11.6) 104 (11.6) 14 (2.75) 2 (0.6)
78.0% (2.1) *** 18.9% (2.1) *** 2.6% (0.5) * 0.3% (0.1)
Data are presented as mean numbers of cells × 10
-3 (S.E.M) and as percentages for individual cell types (n = 8). Significant differences compared to naïve animals
shown as * = P < 0.05, ** = P < 0.01, *** = P < 0.001.
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Figure 6 Th2-biased immunological response. (A) Numbers of CD4
+ T cells recovered from disaggregated lung tissue. (B) Numbers of
eosinophils in tracheal epithelium. (C) Levels of OVA-specific IgE and IgG1 in serum. (D-F) Levels of expression of mRNA for IL-4, IL-5 and IL-13
by CD4
+ T-cells, relative to HPRT. Significant differences compared to virus-infected control animals shown as * = P < 0.05, ** = P < 0.01, *** = P
< 0.001; compared to sham-infected, OVA-challenged animals (Sham/OVA) shown as # = P < 0.05, ## = P < 0.01.
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Page 12 of 15and changes of remodelling were either reduced or
absent in animals sensitised on days 1 and 2 of life.
A possible mechanism for induction of Th2 responses
is revealed by our finding that IL-25 was upregulated in
lung tissue of 14-28 day old animals following neonatal
PVM infection. IL-25 is expressed by airway epithelial
cells and has been implicated in upregulating GATA-3
expression and therefore promoting Th2 differentiation
[49]. Furthermore, IL-25 co-operates with other cyto-
kines in activating dendritic cells to upregulate expres-
sion of class II MHC and various costimulatory
molecules, which collectively function as instructive sig-
nals that drive Th2 polarisation [50,51]. Therefore,
recruitment and activation of dendritic cells will be a
focus of future investigations using this model. IL-25
may also have direct effects on development of an asth-
matic response: when delivered via the airways, this
cytokine induces inflammation, production of Th2 cyto-
kines and AHR which appears to be dependent on
induction of IL-13 via a STAT6-mediated pathway [52].
Our observations in this model provide direct experi-
mental support for a number of epidemological studies.
We recognise that genetic factors may play crucial roles
in determining susceptibility to development of allergic
asthma following early-life viral infection [7] and it is
possible that our experimental data are significantly
influenced by use of the BALB/c strain of mice, which is
predisposed to the development of Th2-biased immune
responses. Nevertheless, this model provides hitherto
unavailable opportunities for investigation of the mole-
cular mechanisms underlying progression of asthma in
childhood.
Conclusion
We have demonstrated that in a novel clinically relevant
experimental model, the interplay between an early-life
pneumovirus infection and subsequent ongoing allergen
challenge is crucial to induction of key features of child-
hood asthma. Elements of the asthmatic phenotype
could be induced following either recovery from viral
infection or allergen sensitisation and challenge. How-
ever, only in the setting of early-life viral infection fol-
lowed by sensitisation via the respiratory tract and
inhalational challenge did animals develop the full con-
stellation of features, including acute and chronic
inflammation of the airways accompanied by a Th2-
biased immunological response which contributed to
their development.
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Table 3 Cytokine secretion by CD4
+ T cells
IL-4 IL-5 IL-13 IFN-g
Naïve 6 (7.6) 28 (6.8) 9 (7.9) 28 (3.8)
Virus control 18 (6.3) 33 (3.8) 16 (5.8) 25 (4.6)
Sham/OVA 10 (5.2) 18 (4.5) 11 (3.7) 6 (2.2)
Virus/nil 26 (7.9) 28 (9.6) 31 (8.2) 31 (6.1)
Virus/OVA 43 (13.1) * 58 (18.0) 49 (7.4) ** 15 (4.1)
Table 4 Relative expression of mRNA for IL-25 in lung
tissue
Day Sham control PVM infected
14 1.13 (0.21) 4.05 (0.57) ***
28 144.1 (76.5) 1005.8 (841)
Table 5 Summary of responses of key experimental groups
Allergic inflammation Th2 response Airway remodelling AHR
Early-life infection alone - - + +++
Sensitisation and challenge alone + ± +++ +
Infection followed by sensitisation and challenge +++ +++ +++ +++
Infection followed by sensitisation and challenge in IL-4Ra
-/- mice - - ++ -
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